- Home
- BTMD vs IMUX Comparison
BTMD vs IMUX Comparison
Compare BTMD & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTMD | IMUX |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.4M | 85.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BTMD | IMUX |
|---|---|---|
| Price | $2.20 | $0.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.00 | $6.00 |
| AVG Volume (30 Days) | 174.0K | ★ 1.6M |
| Earning Date | 03-11-2026 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 270.48 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $195,645,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.80 | N/A |
| P/E Ratio | $2.84 | ★ N/A |
| Revenue Growth | ★ 1.34 | N/A |
| 52 Week Low | $2.18 | $0.51 |
| 52 Week High | $5.93 | $1.39 |
Technical Indicators
Market Signals| Indicator | BTMD | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 33.43 | 57.66 |
| Support Level | $2.19 | $0.59 |
| Resistance Level | $2.42 | $0.71 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 8.24 | 76.31 |
Price Performance
Historical ComparisonAbout BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.